John K. Pratt

2.1k total citations
23 papers, 711 citations indexed

About

John K. Pratt is a scholar working on Infectious Diseases, Organic Chemistry and Hepatology. According to data from OpenAlex, John K. Pratt has authored 23 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Organic Chemistry and 8 papers in Hepatology. Recurrent topics in John K. Pratt's work include Hepatitis C virus research (8 papers), HIV/AIDS drug development and treatment (8 papers) and Mast cells and histamine (5 papers). John K. Pratt is often cited by papers focused on Hepatitis C virus research (8 papers), HIV/AIDS drug development and treatment (8 papers) and Mast cells and histamine (5 papers). John K. Pratt collaborates with scholars based in United States and United Kingdom. John K. Pratt's co-authors include Arthur A. Hancock, Marlon Cowart, William R. Baker, Timothy A. Esbenshade, Chun Wel Lin, Andrew O. Stewart, Curtis M. Tyree, Michael J. Coghlan, Youssef L. Bennani and Peer B. Jacobson and has published in prestigious journals such as Biochemistry, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

John K. Pratt

22 papers receiving 684 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John K. Pratt United States	15	311	207	186	134	103	23	711
Robert G. Gentles United States	17	221 0.7×	345 1.7×	100 0.5×	86 0.6×	146 1.4×	36	669
Ian Stansfield United Kingdom	15	203 0.7×	272 1.3×	256 1.4×	177 1.3×	195 1.9×	23	745
David R. Tortolani United States	13	226 0.7×	477 2.3×	27 0.1×	208 1.6×	95 0.9×	18	728
István Káldor United States	11	219 0.7×	123 0.6×	28 0.2×	111 0.8×	62 0.6×	21	482
Susmith Mukund United States	11	154 0.5×	736 3.6×	10 0.1×	236 1.8×	78 0.8×	13	1.0k
Christopher Moxham United States	9	153 0.5×	487 2.4×	20 0.1×	43 0.3×	42 0.4×	15	734
Jorge Gomez‐Galeno United States	12	251 0.8×	332 1.6×	43 0.2×	112 0.8×	87 0.8×	17	626
Harry B. Marr United States	10	79 0.3×	201 1.0×	56 0.3×	118 0.9×	84 0.8×	13	554
David A. Ellis United States	16	146 0.5×	207 1.0×	23 0.1×	47 0.4×	54 0.5×	38	580
Bheemarao G. Ugarkar United States	16	311 1.0×	378 1.8×	43 0.2×	236 1.8×	127 1.2×	24	791

Countries citing papers authored by John K. Pratt

Since Specialization

Citations

This map shows the geographic impact of John K. Pratt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John K. Pratt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John K. Pratt more than expected).

Fields of papers citing papers by John K. Pratt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John K. Pratt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John K. Pratt. The network helps show where John K. Pratt may publish in the future.

Co-authorship network of co-authors of John K. Pratt

This figure shows the co-authorship network connecting the top 25 collaborators of John K. Pratt. A scholar is included among the top collaborators of John K. Pratt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John K. Pratt. John K. Pratt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sheppard, George S., Le Wang, Lisa Hasvold, et al.. (2018). Abstract 931: Discovery of ABBV-744, a first-in-class highly BDII-selective BET bromodomain inhibitor. Cancer Research. 78(13_Supplement). 931–931.

Pratt, John K., Clarence J. Maring, Warren M. Kati, et al.. (2008). Des-A-ring benzothiadiazines: Inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase. Bioorganic & Medicinal Chemistry Letters. 18(8). 2735–2738. 16 indexed citations

Liu, Yaya, John K. Pratt, Teresa I. Ng, et al.. (2008). Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase. Bioorganic & Medicinal Chemistry Letters. 18(11). 3173–3177. 13 indexed citations

Rockway, Todd W., Rong Zhang, Dachun Liu, et al.. (2006). Inhibitors of HCV NS5B polymerase: Synthesis and structure–activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring. Bioorganic & Medicinal Chemistry Letters. 16(14). 3833–3838. 22 indexed citations

Krueger, A. Chris, Darold L. Madigan, Wen Jiang, et al.. (2006). Inhibitors of HCV NS5B polymerase: Synthesis and structure–activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides. Bioorganic & Medicinal Chemistry Letters. 16(13). 3367–3370. 24 indexed citations

Hancock, Arthur A., Thomas A. Fey, Eugene N. Bush, et al.. (2005). Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy. Inflammation Research. 54(S1). S27–S29. 13 indexed citations

Pratt, John K., Keith F. McDaniel, Clarence J. Maring, et al.. (2005). Inhibitors of HCV NS5B polymerase: synthesis and structure–activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines. Bioorganic & Medicinal Chemistry Letters. 15(6). 1577–1582. 28 indexed citations

Pratt, John K., et al.. (2005). Inhibitors of HCV NS5B Polymerase: Synthesis and Structure—Activity Relationships of N‐1‐Heteroalkyl‐4‐hydroxyquinolon‐3‐yl‐benzothiadiazines.. ChemInform. 36(29). 1 indexed citations

Mo, Hongmei, Liangjun Lu, Edward Tam, et al.. (2005). Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro. Antimicrobial Agents and Chemotherapy. 49(10). 4305–4314. 87 indexed citations

10.

Akritopoulou‐Zanze, Irini, Jehrod Brenneman, Martin Winn, et al.. (2004). Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 14(9). 2079–2082. 20 indexed citations

11.

Curtis, Michael P., John K. Pratt, Marlon Cowart, et al.. (2004). D‐Amino Acid Homopiperazine Amides: Discovery of A‐320436, a Potent and Selective Non‐Imidazole Histamine H₃‐Receptor Antagonist. Archiv der Pharmazie. 337(4). 219–229. 13 indexed citations

12.

Cowart, M. D., Gregory A. Gfesser, Michael A. Curtis, et al.. (2004). The medicinal chemistry of novel H 3 antagonists. Inflammation Research. 53(0). S69–S70. 6 indexed citations

13.

Hancock, Arthur A., Ramin Faghih, Eugene N. Bush, et al.. (2004). In vitro Optimization of Structure Activity Relationships of Analogues of A‐331440 Combining Radioligand Receptor Binding Assays and Micronucleus Assays of Potential Antiobesity Histamine H₃ Receptor Antagonists. Basic & Clinical Pharmacology & Toxicology. 95(3). 144–152. 22 indexed citations

14.

Elmore, Steven W., John K. Pratt, Michael J. Coghlan, et al.. (2004). Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorganic & Medicinal Chemistry Letters. 14(7). 1721–1727. 41 indexed citations

15.

Cowart, Marlon, John K. Pratt, Andrew O. Stewart, et al.. (2003). A new class of potent non-imidazole H3 antagonists: 2-aminoethylbenzofurans. Bioorganic & Medicinal Chemistry Letters. 14(3). 689–693. 74 indexed citations

16.

Zheng, Guo Zhu, Yue Mao, John K. Pratt, et al.. (2003). Adenosine kinase inhibitors: polar 7-Substitutent of pyridopyrimidine derivatives improving their locomotor selectivity. Bioorganic & Medicinal Chemistry Letters. 13(18). 3041–3044. 34 indexed citations

17.

Kym, Philip R., Michael E. Kort, Michael J. Coghlan, et al.. (2003). Nonsteroidal Selective Glucocorticoid Modulators: The Effect of C-10 Substitution on Receptor Selectivity and Functional Potency of 5-Allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. Journal of Medicinal Chemistry. 46(6). 1016–1030. 86 indexed citations

18.

Meyer, Michael D., Robert J. Altenbach, Fatima Z. Basha, et al.. (2001). Structure−Activity Studies for a Novel Series of Bicyclic Substituted Hexahydrobenz[e]isoindole α_1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia. Journal of Medicinal Chemistry. 44(12). 1971–1985. 29 indexed citations

19.

Elmore, Steven W., Michael J. Coghlan, David D. Anderson, et al.. (2001). Nonsteroidal Selective Glucocorticoid Modulators: the Effect of C-5 Alkyl Substitution on the Transcriptional Activation/Repression Profile of 2,5-Dihydro-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. Journal of Medicinal Chemistry. 44(25). 4481–4491. 94 indexed citations

20.

Phillion, Dennis P. & John K. Pratt. (1992). A New Method for Hydrolyzing 2-Aryl-4,4-Dimethyl-2-Oxazolines to Aryl Carboxylic Acids. Synthetic Communications. 22(1). 13–22. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact